On March 8, 2019 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that Dr. Claus Møller, MD, Ph.D., Chief Executive Officer of Y-mAbs Therapeutics will provide an overview and update on the company’s business at Cowen’s 39th Annual Health Care Conference in Boston, Massachusetts (Press release, Y-mAbs Therapeutics, MAR 8, 2019, http://ir.ymabs.com/news-releases/news-release-details/y-mabs-therapeutics-present-cowens-39th-annual-health-care [SID1234534140]). The presentation will take place on Tuesday, March 12, 2019, at 8:40 AM Eastern Daylight Time, and the presentation deck will be made available on the Company website at the time of presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!